These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36422852)

  • 1. Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies.
    Thurston AW; Osborne DW; Snyder S; Higham RC; Burnett P; Berk DR
    Am J Clin Dermatol; 2023 Mar; 24(2):315-324. PubMed ID: 36422852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.
    Lebwohl MG; Kircik LH; Moore AY; Stein Gold L; Draelos ZD; Gooderham MJ; Papp KA; Bagel J; Bhatia N; Del Rosso JQ; Ferris LK; Green LJ; Hebert AA; Jones T; Kempers SE; Pariser DM; Yamauchi PS; Zirwas M; Albrecht L; Devani AR; Lomaga M; Feng A; Snyder S; Burnett P; Higham RC; Berk DR
    JAMA; 2022 Sep; 328(11):1073-1084. PubMed ID: 36125472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study.
    Papp KA; Gooderham M; Droege M; Merritt C; Osborne DW; Berk DR; Thurston AW; Smith VH; Welgus H
    J Drugs Dermatol; 2020 Aug; 19(8):734-740. PubMed ID: 32845114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roflumilast 0.3% Cream: a Phosphodiesterase 4 Inhibitor for the Treatment of Chronic Plaque Psoriasis.
    Nicolas SE; Bear MD; Kanaan AO; Coman OA; Dima L
    Am J Ther; 2023 Nov-Dec 01; 30(6):e535-e542. PubMed ID: 37921681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I randomized trial to assess the effect on skin infiltrate thickness and tolerability of topical phosphodiesterase inhibitors in the treatment of psoriasis vulgaris using a modified psoriasis plaque test.
    Snape SD; Wigger-Alberti W; Goehring UM
    Br J Dermatol; 2016 Sep; 175(3):479-86. PubMed ID: 27038440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trial of Roflumilast Cream for Chronic Plaque Psoriasis.
    Lebwohl MG; Papp KA; Stein Gold L; Gooderham MJ; Kircik LH; Draelos ZD; Kempers SE; Zirwas M; Smith K; Osborne DW; Trotman ML; Navale L; Merritt C; Berk DR; Welgus H;
    N Engl J Med; 2020 Jul; 383(3):229-239. PubMed ID: 32668113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Topical Roflumilast for the Treatment of Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    de Moraes-Souza R; Chahine Chater R; Pera Calvi I; Mesquita Y; Sarto R; Lapenda I; Figueiredo Pereira L; Moury L; Herranz-Pinto P
    Clin Drug Investig; 2024 Sep; 44(9):655-665. PubMed ID: 39172296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical Roflumilast for Plaque Psoriasis.
    O'Toole A; Gooderham M
    Skin Therapy Lett; 2023 Sep; 28(5):1-4. PubMed ID: 37734074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial.
    Stein Gold L; Adam DN; Albrecht L; Alonso-Llamazares J; Ferris LK; Gooderham MJ; Hong HC; Kempers SE; Kircik LH; Lebwohl M; Loo WJ; Nahm WK; Papp KA; Stewart D; Toth DP; Zirwas M; Krupa D; Snyder S; Burnett P; Higham R; Berk DR
    J Am Acad Dermatol; 2024 Aug; 91(2):273-280. PubMed ID: 38556093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Review of Topical Roflumilast for the Treatment of Plaque Psoriasis.
    Pixley JN; Schaetzle T; Feldman SR
    Ann Pharmacother; 2023 Aug; 57(8):966-969. PubMed ID: 36420929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis.
    Hermann R; Nassr N; Lahu G; Péterfai E; Knoerzer D; Herzog R; Zech K; de Mey C
    Clin Pharmacokinet; 2007; 46(5):403-16. PubMed ID: 17465639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.
    Lahu G; Hünnemeyer A; Diletti E; Elmlinger M; Ruth P; Zech K; McCracken N; Facius A
    Clin Pharmacokinet; 2010 Sep; 49(9):589-606. PubMed ID: 20690782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical roflumilast for the treatment of psoriasis.
    Drakos A; Vender R; Torres T
    Expert Rev Clin Immunol; 2023; 19(9):1053-1062. PubMed ID: 37243575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide.
    Lahu G; Huennemeyer A; Herzog R; McCracken N; Hermann R; Elmlinger M; Zech K
    Int J Clin Pharmacol Ther; 2009 Apr; 47(4):236-45. PubMed ID: 19356389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide.
    von Richter O; Lahu G; Huennemeyer A; Herzog R; Zech K; Hermann R
    Clin Pharmacokinet; 2007; 46(7):613-22. PubMed ID: 17596106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of Roflumilast and Its Active Metabolite Roflumilast N-Oxide in Healthy Chinese Subjects After Single and Multiple Oral Doses.
    Li Q; Wang Y; Liu L; Ma P; Ding L
    Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):371-381. PubMed ID: 27306372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZORYVE
    Gupta AK; Ravi SP; Vincent K; Abramovits W
    Skinmed; 2023; 21(5):357-359. PubMed ID: 37945365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide.
    Lahu G; Nassr N; Herzog R; Elmlinger M; Ruth P; Hinder M; Huennemeyer A
    J Clin Pharmacol; 2011 Apr; 51(4):586-93. PubMed ID: 20466871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and Safety of Icotinib Hydrochloride Cream in Patients with Mild to Moderate Chronic Plaque Psoriasis: A Randomized Double-Blind Vehicle-Controlled Phase 1 Study.
    Liu L; Lou H; Zhou J; Shen Y; Zheng M; Ruan Z
    Biomed Res Int; 2019; 2019():9072683. PubMed ID: 31187048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the safety and efficacy of tapinarof and roflumilast topical therapies in the management of mild-to-moderate plaque psoriasis.
    Ghani H; Podwojniak A; Tan IJ; Parikh AK; Sanabria B; Rao B
    Skin Res Technol; 2024 Sep; 30(9):e70041. PubMed ID: 39206797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.